Psychotropic medication usage in sporadic versus genetic behavioral-variant frontotemporal dementia

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2024-12-23 DOI:10.1002/alz.14448

Juan-Camilo Vargas-Gonzalez, Nico Dimal, Kasey Cortez, Hilary Heuer, Leah K. Forsberg, Brian S. Appleby, Sami Barmada, Andrea Bozoki, David Clark, Yann Cobigo, R. Ryan Darby, Bradford C. Dickerson, Kimiko Domoto-Reilly, Douglas R. Galasko, Daniel H. Geschwind, Nupur Ghoshal, Neill R. Graff-Radford, Ian M. Grant, David Irwin, Ging-Yuek Robin Hsiung, Lawrence S. Honig, Kejal Kantarci, Gabriel C. Léger, Irene Litvan, Ian R. Mackenzie, Joseph C. Masdeu, Mario F. Mendez, Chiadi U. Onyike, Belen Pascual, Peter Pressman, Eliana Marisa Ramos, Erik D. Roberson, Emily Rogalski, Brad F. Boeve, Adam L. Boxer, Howie J. Rosen, Maria Carmela Tartaglia

引用次数: 0

Abstract

Psychotropic medication (PM) use in behavioral-variant frontotemporal dementia (bvFTD) is higher than in other dementias. However, no information exists on whether PM use differs between sporadic and genetic bvFTD.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.